NeurAxis, Inc. (NRXS)

Over the past six months, NeurAxis, Inc.'s stock price has been impacted by several events. The company received FDA 510(k) clearance for its PENFS device to treat functional abdominal pain associated with functional dyspepsia (FD) and FD-related nausea in patients aged 8 years and older. The company has significantly expanded its insurance coverage, adding approximately 45 million covered lives. A Category I CPT code for Percutaneous Electrical Nerve Field Stimulation (PENFS) procedures became effective on January 1, 2026, establishing a permanent reimbursement pathway. In Q3 2025, revenues increased 22% year-over-year to $811,000, but operating losses widened to $2.1 million. In Q2 2025, revenues increased 46% year-over-year to $894,000. In Q1 2025, revenues increased 39% year-over-year to $896,000. Craig-Hallum raised Neuraxis' price target to $8 from $7. NeurAxis secured a Veterans Affairs Federal Supply Schedule Contract. The share price increased by 93.19% between January 2, 2025, and December 31, 2025.

There is no explicit information available to indicate demand seasonality for NeurAxis, Inc.'s products and services. The company has reported consistent year-over-year revenue growth across different quarters, suggesting a relatively stable demand pattern rather than significant seasonal fluctuations.

NeurAxis, Inc. is a medical technology company in the Healthcare sector, focusing on neuromodulation therapies. Their primary product is IB-Stim, an FDA-cleared PENFS system for patients aged 8-21 with functional abdominal pain associated with IBS and FD. They also offer the Rectal Expulsion Device (RED) to evaluate neuromuscular function related to rectal expulsion.

NeurAxis, Inc. is headquartered in Carmel, Indiana, with a distribution center in Versailles, Indiana, and primarily operates within the United States.

NeurAxis, Inc.'s brand reputation has been positively impacted by expanding insurance coverage for its PENFS technology, inclusion in clinical practice guidelines, and the new Category I CPT code.

NeurAxis, Inc. is owned by a mix of institutional shareholders, insiders, and retail investors. 7.60% of the stock is held by institutional investors, 26.56% by NeurAxis insiders, and 65.84% by retail investors. Major institutional owners include AIGH Capital Management LLC, Parsons Capital Management Inc/RI, Vanguard Group Inc, Geode Capital Management, Llc, Citadel Advisors Llc, Money Concepts Capital Corp, Stifel Financial Corp, and XTX Topco Ltd. Major individual owners (insiders) include Brian Hannasch, Christopher Robin Brown, and Gary Merril Peterson.